Physician profile
Sidney M Crain
NPI 1366520041
$2,758.86
in general payments reported to CMS, 2019-2025
34 companies · $1,208 in 2025
The $1,208 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2023: $360 · 2024: $324 · 2025: $1,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433 · Honoraria: $360 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.80 |
| Honoraria | $360.00 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $360.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $281.90 | 2019-2025 | Enhertu, Calquence, Tagrisso |
| Janssen Biotech, INC. | $242.22 | 2019-2025 | Darzalex, Talvey, Erleada |
| Medtronic USA, INC. | $225.10 | 2019 | |
| Abbvie INC. | $199.57 | 2019-2024 | |
| Genzyme Corporation | $189.20 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $150.75 | 2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $124.51 | 2025 | |
| Novartis Pharmaceuticals Corporation | $116.79 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $79.03 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| Glaxosmithkline, LLC. | $70.59 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Celgene Corporation | $64.35 | 2019-2024 | Reblozyl |
| Incyte Corporation | $57.97 | 2025 | Monjuvi, Jakafi, Niktimvo |
| Takeda Pharmaceuticals U.S.A., INC. | $57.00 | 2024-2025 | Vonvendi, Advate |
| Bayer Healthcare Pharmaceuticals INC. | $56.81 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $32.84 | 2025 | Optune Gio |
| Pfizer INC. | $32.40 | 2019-2025 | |
| Teleflex LLC | $32.13 | 2019 | |
| Exelixis INC. | $30.85 | 2019-2025 | Cabometyx |
| Springworks Therapeutics, INC. | $30.68 | 2025 | Ogsiveo |
| Pharmaessentia USA Corporation | $30.10 | 2025 | Besremi |
| Puma Biotechnology, INC. | $28.64 | 2025 | |
| Beigene USA, INC. | $28.58 | 2025 | Brukinsa |
| Iovance Biotherapeutics, INC. | $27.19 | 2025 | Amtagvi |
| Astellas Pharma US INC | $24.26 | 2025 | Vyloy |
| Pharmacosmos Therapeutics INC. | $24.15 | 2025 | Monoferric |
| Dendreon Pharmaceuticals LLC | $23.92 | 2019 | |
| Tersera Therapeutics LLC | $22.60 | 2025 | Xermelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.26 | 2025 | |
| Agios Pharmaceuticals, INC. | $21.53 | 2024 | Pyrukynd |
| Tempus Ai, INC | $20.24 | 2024 | Xt Cdx |
| Tactile Systems Technology INC | $19.85 | 2025 | Flexitouch Plus, Nimbl |
| Sobi, INC | $16.73 | 2025 | |
| Accord Healthcare, INC. | $14.12 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Crain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.